Vaxil BioTherapeutics debuts on Tel Aviv Stock Exchange

Vaxil BioTherapeutics made its debut on the Tel Aviv Stock Exchange through a merger with Sheldonco. Sheldonco acquired Vaxil in full, according to a release, giving Vaxil shareholders 56% stake in Sheldonco on a fully diluted basis. The holding will shoot up to 74% in Sheldonco if the developer of cancer and infectious disease vaccines hits two research milestones. Release | Story (sub. req.)

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.